
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
AAK1 (AP2 associated kinase 1) encodes a serine/threonine protein kinase that regulates clathrin-mediated receptor endocytosis. AAK1 phosphorylates a subunit of the adaptor protein complex 2, promoting recognition of receptor sorting signals and assembly of endocytic machinery. Its kinase activity is stimulated by clathrin, and AAK1 also contributes to regulation of Notch signaling. The protein has additionally been implicated in clathrin-dependent viral entry, including entry of rabies virus.
T98G is a human glioblastoma multiforme cell line derived from a tumor of a 61-year-old male patient. The cells exhibit an indefinite lifespan and anchorage-independent growth properties, while retaining the ability to enter a viable G1-arrested state under serum deprivation conditions. T98G is used as a model for studying glioblastoma biology, cell cycle regulation, tumor growth mechanisms, and therapeutic responses.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_014911
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?